The effect of recording this immaterial error correction affects the presentation of the balance sheets as of June 30, 2013 and 2012, the consolidated statements of comprehensive (loss) income and statements of cash flows for the fiscal years ended June 30, 2013, 2012 and 2011 for certain line items as set forth below (in thousands):
| As of June 30, 2013 | As of June 30, 2012 | |||||||||||||||
| (As Reported) |
(As Revised) |
(As Reported) |
(As Revised) |
|||||||||||||
|
Balance Sheets |
||||||||||||||||
|
Accounts payable and accrued expenses |
$ | 7,165 | $ | 3,951 | $ | 5,412 | $ | 2,982 | ||||||||
|
Total current liabilities |
9,945 | 6,731 | 5,595 | 3,165 | ||||||||||||
|
Accumulated deficit |
(229,254 | ) | (226,040 | ) | (217,088 | ) | (214,658 | ) | ||||||||
|
Total Immunomedics, Inc. stockholders’ equity |
36,966 | 40,180 | 32,027 | 34,457 | ||||||||||||
|
Total stockholders’ equity |
36,581 | 39,795 | 31,739 | 34,169 | ||||||||||||
| Fiscal Year Ended June 30, 2013 |
Fiscal Year Ended June 30, 2012 |
Fiscal Year Ended June 30, 2011 |
||||||||||||||||||||||
| (As Reported) |
(As Revised) |
(As Reported) |
(As Revised) |
(As Reported) |
(As Revised) |
|||||||||||||||||||
|
Statements of Comprehensive (Loss) Income |
||||||||||||||||||||||||
|
Research and development |
$ | 29,165 | $ | 28,381 | $ | 24,824 | $ | 24,256 | $ | 25,369 | $ | 24,537 | ||||||||||||
|
Total costs and expenses |
36,538 | 35,754 | 31,860 | 31,292 | 33,732 | 32,900 | ||||||||||||||||||
|
Operating (loss) income |
(31,576 | ) | (30,792 | ) | 874 | 1,442 | (19,023 | ) | (18,191 | ) | ||||||||||||||
|
(Loss) income before income tax expense |
(12,226 | ) | (11,442 | ) | 906 | 1,474 | (15,135 | ) | (14,303 | ) | ||||||||||||||
|
Net (loss) income |
(12,270 | ) | (11,486 | ) | 696 | 1,264 | (15,244 | ) | (14,412 | ) | ||||||||||||||
|
Net (loss) income attributable to Immunomedics, Inc. stockholders |
(12,165 | ) | (11,381 | ) | 810 | 1,378 | (15,070 | ) | (14,238 | ) | ||||||||||||||
|
Comprehensive (loss) income |
(12,189 | ) | (11,405 | ) | 382 | 950 | (15,191 | ) | (14,359 | ) | ||||||||||||||
|
Comprehensive (loss) income attributable to Immunomedics, Inc. stockholders |
(12,084 | ) | (11,300 | ) | 495 | 1,063 | (15,017 | ) | (14,185 | ) | ||||||||||||||
|
Net (loss) income per common share attributable to Immunomedics Inc. to common stockholders – basic |
(0.16 | ) | (0.15 | ) | 0.01 | 0.02 | (0.20 | ) | (0.19 | ) | ||||||||||||||
|
Net (loss) income per common share attributable to Immunomedics Inc. common stockholders – fully diluted |
(0.16 | ) | (0.15 | ) | 0.01 | 0.02 | (0.20 | ) | (0.19 | ) | ||||||||||||||
|
Weighted average number of common shares outstanding – basic |
78,040 | 78,040 | 75,481 | 75,481 | 75,313 | 75,313 | ||||||||||||||||||
|
Weighted average number of common shares outstanding – fully diluted |
78,040 | 78,040 | 76,174 | 76,174 | 75,313 | 75,313 | ||||||||||||||||||
|
Statements of Cash Flows |
||||||||||||||||||||||||
|
Changes in accounts payable and accrued expenses |
1,751 | 967 | 67 | (501 | ) | 1,242 | 410 | |||||||||||||||||